Research programme: Campylobacter jejuni vaccines: Scandinavian Biopharma/VaxAlta
Alternative Names: C. jejuni vaccineLatest Information Update: 28 Jan 2026
At a glance
- Originator VaxAlta
- Class Antidiarrhoeals; Bacterial vaccines
- Mechanism of Action
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diarrhoea
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for research development in Diarrhoea in USA (Parenteral)
- 22 Dec 2021 VaxAlta enters into licensing agreement with Scandinavian Biopharma for the development of Campylobacter jejuni vaccines
- 22 Dec 2021 Early research in Diarrhoea in USA (Parenteral)